Oral semaglutide reduces cardiovascular event rates in high-risk patients
1. In this randomized controlled trial, oral semaglutide significantly reduced the risk of adverse cardiovascular events in patients with type ...
Tag: MACE
ST-elevation myocardial infarction with nonobstructive coronary arteries associated with significant mortality
1. Patients with ST-elevation myocardial infarction (STEMI) with nonobstructive coronary arteries (MINOCA) and MINOCA-mimicking disease demonstrated significantly higher five-year mortality ...
Computed Tomography coronary calcium scores may predict risk of cardiovascular events in cancer patients
1. Despite lower prevalence of traditional cardiovascular risk factors, cancer patients were observed to have similar cardiovascular disease (CVD) events ...
GLP-1 receptor agonists lower adverse cardiac event risk in veterans with type 2 diabetes
1. In this retrospective cohort study, glucagon-like peptide-1 receptor agonists (GLP1RA) were associated with a lower risk of major adverse ...
Quick Take: Body composition and cardiovascular events in patients with colorectal cancer
Patients with colorectal cancer (CRC) are 2-4 times more likely to develop cardiovascular disease, as compared to individuals without a ...
2 Minute Medicine Rewind May 20, 2019
Association between incidence exposure to benzodiazepines in early pregnancy and risk of spontaneous abortion Previous studies have shown that benzodiazepine ...
Dapagliflozin associated with reduced hospitalization rate for heart failure
1. Among patients with type 2 diabetes and established or multiple risk factors for cardiovascular disease (CVD), dapagliflozin was noninferior ...
#VisualAbstract: Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction The ARTEMIS Randomized Clinical Trial
1. In this randomized controlled trial, medication vouchers were associated with a small increase in patient-reported persistence with P2Y12 inhibitors for ...
Medication co-payment vouchers for P2Y12 inhibitors not associated with reduced major adverse cardiovascular events
1. In this randomized controlled trial, medication vouchers were associated with a small increase in patient-reported persistence with P2Y12 inhibitors ...
The REDUCE-IT trial: Icosapent ethyl reduces ischemic event risk in patients with hypertriglyceridemia despite statin use
1. After a median follow-up of 4.9 years, patients with elevated triglyceride levels despite statin use treated with icosapent ethyl ...
